Effects of antiresorptive agents on body composition: a case-control retrospective study.

IF 1.4 Q3 RHEUMATOLOGY
Suhel Gabriele Al Khayyat, Giuseppe Fogliame, Edoardo Conticini, Virginia Berlengiero, Paolo Falsetti, Stefano Gentileschi, Caterina Baldi, Marco Bardelli, Luca Cantarini, Bruno Frediani
{"title":"Effects of antiresorptive agents on body composition: a case-control retrospective study.","authors":"Suhel Gabriele Al Khayyat,&nbsp;Giuseppe Fogliame,&nbsp;Edoardo Conticini,&nbsp;Virginia Berlengiero,&nbsp;Paolo Falsetti,&nbsp;Stefano Gentileschi,&nbsp;Caterina Baldi,&nbsp;Marco Bardelli,&nbsp;Luca Cantarini,&nbsp;Bruno Frediani","doi":"10.5114/reum.2023.124335","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Osteoporosis is the most represented metabolic bone disease and is characterized by the reduction of bone mineral density (BMD), exposing patients to high fracture risk and disability. Bisphosphonates (BPs) are the main compounds exploited in treatment of osteoporosis and significantly reduce fracture risk. Sarcopenia is the pathological reduction of muscle masses and strength, and many studies highlighted its co-existence in patients with impaired bone mass. Indeed, the pathological reduction of lean tissue has been linked to a higher risk of falls and, consequently, fractures and disability. Moreover, the pathological reduction of lean tissue seems to share many pathological mechanisms with impaired bone strength and structure; thus, in this context, we decided to conduct a retrospective case-control study aimed at evaluating the effects of BPs on lean mass and body composition.</p><p><strong>Material and methods: </strong>We enrolled postmenopausal women from our metabolic bone diseases outpatient clinic who underwent at least two consecutive dual-energy X-ray absorptiometry (DXA) examinations concomitantly to the beginning of an antiresorptive agent. The body composition of patients and controls was compared by fat masses, lean masses and android-to-gynoid ratio (A/G ratio).</p><p><strong>Results: </strong>A total of 64 female subjects were considered for the study: 41 starting a BPs and 23 without treatment were used as control. The fat masses and lean masses appeared to be unaffected by BPs. Conversely, A/G ratio was lower in BPs group after 18 months of therapy compared to baseline (<i>p</i> < 0.05). From the stratification based on the single BP we failed to highlight any significant difference between the tested variables.</p><p><strong>Conclusions: </strong>Bisphosphonates treatment did not modify lean tissues, however a significant reduction of A/G ratio in BP group was documented. Thus the BPs seems to act on patients body composition and extra-skeletal tissues but larger prospective studies are needed to evaluate whether these modifications have clinical relevance.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/2c/RU-61-156907.PMC10201384.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/reum.2023.124335","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Osteoporosis is the most represented metabolic bone disease and is characterized by the reduction of bone mineral density (BMD), exposing patients to high fracture risk and disability. Bisphosphonates (BPs) are the main compounds exploited in treatment of osteoporosis and significantly reduce fracture risk. Sarcopenia is the pathological reduction of muscle masses and strength, and many studies highlighted its co-existence in patients with impaired bone mass. Indeed, the pathological reduction of lean tissue has been linked to a higher risk of falls and, consequently, fractures and disability. Moreover, the pathological reduction of lean tissue seems to share many pathological mechanisms with impaired bone strength and structure; thus, in this context, we decided to conduct a retrospective case-control study aimed at evaluating the effects of BPs on lean mass and body composition.

Material and methods: We enrolled postmenopausal women from our metabolic bone diseases outpatient clinic who underwent at least two consecutive dual-energy X-ray absorptiometry (DXA) examinations concomitantly to the beginning of an antiresorptive agent. The body composition of patients and controls was compared by fat masses, lean masses and android-to-gynoid ratio (A/G ratio).

Results: A total of 64 female subjects were considered for the study: 41 starting a BPs and 23 without treatment were used as control. The fat masses and lean masses appeared to be unaffected by BPs. Conversely, A/G ratio was lower in BPs group after 18 months of therapy compared to baseline (p < 0.05). From the stratification based on the single BP we failed to highlight any significant difference between the tested variables.

Conclusions: Bisphosphonates treatment did not modify lean tissues, however a significant reduction of A/G ratio in BP group was documented. Thus the BPs seems to act on patients body composition and extra-skeletal tissues but larger prospective studies are needed to evaluate whether these modifications have clinical relevance.

抗吸收药物对机体成分的影响:一项病例对照回顾性研究。
骨质疏松症是最具代表性的代谢性骨病,其特点是骨密度(BMD)降低,使患者面临骨折和残疾的高风险。双膦酸盐(BPs)是治疗骨质疏松症的主要化合物,可显著降低骨折风险。肌少症是肌肉质量和力量的病理性减少,许多研究强调其在骨量受损患者中共存。事实上,瘦肉组织的病理性减少与较高的跌倒风险有关,从而导致骨折和残疾。此外,瘦肉组织的病理性减少似乎与骨强度和结构受损有许多病理机制;因此,在此背景下,我们决定进行一项回顾性病例对照研究,旨在评估bp对瘦体重和身体组成的影响。材料和方法:我们招募了来自代谢性骨病门诊的绝经后妇女,她们至少连续两次接受双能x线吸收测定(DXA)检查,同时开始使用抗吸收药物。通过脂肪质量、瘦肉质量和雌雄比(A/G ratio)比较患者和对照组的身体组成。结果:共有64名女性受试者被纳入研究:41名开始bp, 23名未治疗作为对照。胖子和瘦子似乎不受bp的影响。相反,BPs组治疗18个月后A/G比低于基线(p < 0.05)。从基于单个BP的分层中,我们未能突出测试变量之间的任何显著差异。结论:双膦酸盐治疗没有改变瘦组织,但显著降低了BP组的a /G比率。因此,bp似乎对患者的身体成分和骨骼外组织起作用,但需要更大规模的前瞻性研究来评估这些改变是否具有临床相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Reumatologia
Reumatologia Medicine-Rheumatology
CiteScore
2.70
自引率
0.00%
发文量
44
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信